grey market retatrutide ⚠️ BEWARE OF SOLD ONLINE! There are many "miracle" weight loss solutions spreading on social media, but not all are safe. Retatrutide is still undergoing clinical trials and NO FDA APPROVAL Comment: The rise of unregulated

That catches people off-guard, but the behavioral methodology underneath is the most evidence-based in our list

The first head-to-head clinical trial (SURMOUNT-5, published in the New England Journal of Medicine in 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks compared to 13.7% for semaglutide approximately 47% greater relative weight loss

In 2025, KFF reported that 19% of employers with 200+ workers and 43% with 5,000+ workers covered GLP-1s for weight loss, and employers are expected to revisit coverage and cost-containment strategies each year as demand remains high

Comparison of the Effects of 10 GLP-1 RA and SGLT2 Inhibitor Interventions on Cardiovascular, Mortality, and Kidney Outcomes in Type 2 Diabetes: A Network Meta-Analysis of Large Randomized Trials

Only a licensed clinician can determine whether GLP-1 treatment is appropriate for a specific individual

The combination also increases the risk of nausea and can further stress the GI tract during the window when side effects are already most likely